ZL 82
Alternative Names: ZL-82Latest Information Update: 28 May 2026
At a glance
- Originator Chengdu Zenitar Biomedical Technology
- Class Anti-inflammatories; Antirheumatics; Skin disorder therapies
- Mechanism of Action Janus kinase 3 inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atopic dermatitis
- Phase I Ulcerative colitis
- Preclinical Vitiligo
- No development reported Inflammatory bowel diseases; Rheumatoid arthritis
Most Recent Events
- 28 May 2026 No recent reports of development identified for phase-I development in Inflammatory-bowel-diseases(In volunteers, In adults) in China (PO, Tablet)
- 28 May 2026 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers, In adults) in China (PO, Tablet)
- 03 Feb 2026 Phase-II clinical trials in Atopic dermatitis in China (PO)(NCT07193589)